Pharmacogenomic Research in Korean Patients With Hepatitis C
The aim of this study is to investigate the relationships between drug response and the host genetic factors, viral factors and clinical factors in chronic hepatitis C patients (HCV). And thus, the investigators are trying to develop the pharmacogenomic guideline in the Korean patients with HCV.
Chronic Hepatitis C
|Study Design:||Observational Model: Cohort|
|Official Title:||Pharmacogenomic Research for Prediction of Drug Response in Korean Patients With Hepatitis C|
- Sustained virological response (SVR) [ Time Frame: 24 weeks after the end of treatment ] [ Designated as safety issue: No ]Undetectable HCV RNA in serum ( <15 IU/ml ) 24 weeks after the end of treatment
- Anemia [ Time Frame: 4 weeks after start of treatment ] [ Designated as safety issue: Yes ]
- a reduction in Hemoglobin of >3.0 g/dL
- a reduction in Hemoglobin levels to 10.0g/dL.
Biospecimen Retention: Samples With DNA
DNA extracted from blood
|Study Start Date:||July 2011|
|Study Completion Date:||March 2013|
|Primary Completion Date:||March 2013 (Final data collection date for primary outcome measure)|
A patients who achieved SVR (sustained virologic response)
A patients who not achieved SVR (sustained virologic response)